디지털 치료제 시장 : 솔루션 유형별, 치료 유형별, 솔루션 목적별, 비즈니스 모델 유형별, 대상 치료 영역별, 주요 지역별 - 업계 동향과 세계 예측(-2035년)

Digital Therapeutics Market by Type of Solution, Type of Therapy, Purpose of Solution, Type of Business Model, Target Therapeutic Area and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,691,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,758,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,778,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,096,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 디지털 치료제 시장 규모는 2035년까지의 예측 기간 중 19.32%의 CAGR로 확대하며, 현재 28억 3,000만 달러에서 2035년까지 197억 6,000만 달러로 성장할 것으로 예측됩니다.

디지털 헬스는 세계 규모로 헬스케어를 개선하는 가장 유망한 어프로치의 하나입니다. 최근 디지털 치료제는 특히 만성질환이나 정신건강 문제 등 약리학적 개입으로 다루기 어려운 질환에 대해 여러 이해관계자들로부터 큰 관심을 받고 있습니다. 또한 디지털 헬스 솔루션의 활용을 촉진하기 위한 지속적인 노력과 함께 환자 중심의 기능 및 첨단 기술 접목이 이루어지고 있으며, 장기적으로 디지털 헬스 솔루션의 채택률이 크게 향상될 것으로 예상됩니다. 반면, 환자와 직원의 낮은 디지털 리터러시 수준은 여전히 큰 우려의 대상입니다. 디지털 헬스의 지속적인 발전과 함께 병원들은 이러한 디지털 솔루션을 도입하기 위해 직원들을 대상으로 인식 확산 및 디지털 솔루션 도입에 대한 세션을 제공하는 노력을 시작했습니다.

디지털 치료제의 인기가 높아지고 새로운 기술이 등장함에 따라 디지털 치료제 기업은 더 높은 채택을 보장하기 위해 첨단 기술을 각 포트폴리오에 통합하고 있습니다. 환자들의 인식이 높아지고 기존 수요를 충족시키기 위한 정부 및 업계 이해관계자들의 적극적인 노력에 힘입어 디지털 치료제 시장은 유리한 성장 기회를 목격할 것으로 예상됩니다.

현재 415개 이상의 디지털 치료제가 다양한 적응증에 대해 시판 중이거나 개발 중이고, 그 중 45개 이상% 독립형 소프트웨어 용도으로 제공되고 있습니다.

이 중 220개의 디지털·솔루션이 여성 건강에 초점을 맞추고 있으며, 약 30%가 생식 의료 관련 용도를 대상으로 하고 있습니다.

세계의 디지털 치료제 시장에 대해 조사했으며, 시장의 개요와 솔루션 유형별, 치료 유형별, 솔루션 목적별, 비즈니스 모델 유형별, 대상 치료 영역별, 주요 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 서문

제2장 개요

제3장 서론

제4장 현재 시장 구도

제5장 제품 경쟁력 분석

• 챕터 개요
• 전제/주요 파라미터
• 조사 방법
• 주요 치료 영역

제6장 기업 개요

• 챕터 개요
• Akili Interactive
• Big Health
• dreem
• Kaia Health
• MindMaze
• Omada Health
• Pear Therapeutics
• Vida Health
• Voluntis
• WellDoc
• Wellthy Therapeutics

제7장 임상시험 분석

• 챕터 개요
• 범위와 조사 방법
• 디지털 치료제 : 임상시험 분석
• 임상 엔드포인트 분석

제8장 자금조달과 투자 분석

제9장 파트너십과 협업

• 챕터 개요
• 파트너십 모델
• 디지털 치료제 : 파트너십과 협업 리스트

제10장 시장 참여 전략

제11장 BOWMAN CLOCK의 가격 전략 분석

제12장 시장 예측

• 챕터 개요
• 예측 조사 방법과 주요 전제
• 2035년까지의 세계 디지털 치료 시장
• 디지털 치료 시장 : 2035년까지 솔루션 유형별 분석
• 디지털 치료 시장 : 2035년까지 솔루션 목적별 분석
• 디지털 치료 시장 : 2035년까지 치료 유형별 분석
• 디지털 치료 시장 : 2035년까지 비즈니스 모델별 분석
• 디지털 치료 시장 : 2035년까지 치료 영역별 분석
• 디지털 치료 시장 : 2035년까지 지역별 분석
• 결론

제13장 여성 디지털 헬스 : 새로운 개념의 출현

제14장 SWOT 분석

제15장 이그제큐티브 인사이트

제16장 결론

제17장 부록 1 : 표 형식 데이터

제18장 부록 2 : 기업·단체 리스트

KSA

영문 목차

영문목차

DIGITAL THERAPEUTICS MARKET: OVERVIEW

As per Roots Analysis, the global digital therapeutics market is estimated to grow from USD 2.83 billion in the current year to USD 19.76 billion by 2035, at a CAGR of 19.32% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Solution

• Software Solution
• Gaming Solution
• Combination Solution

Type of Therapy

• Curative
• Preventive

Purpose of Solution

• Medication Replacement
• Medication Augmentation

Type of Business Model

• B2B
• B2C

Therapeutic Area

• Cardiovascular Disorders
• Chronic Pain
• Mental Health Problems
• Metabolic Disorders
• Neurological Disorders
• Respiratory Disorders
• Sleep Disorders
• Substance Use Disorders
• Other Disorders

Key Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa
• Rest of the World

DIGITAL THERAPEUTICS MARKET: GROWTH AND TRENDS

Digital health is one of the most promising approaches to improving healthcare, at a global scale. In recent years, digital therapeutics have garnered significant interest from several stakeholders, especially for conditions that remain poorly addressed by pharmacological interventions, including chronic diseases and mental health issues. Moreover, given the ongoing efforts to promote the use of digital health solutions, along with the incorporation of patient centric features and advanced technologies, their adoption rates are anticipated to improve significantly in the long term. On the contrary, low digital literacy rates among patients and staff members are a major concern. With persistent advancements in digital health, hospitals have started taking initiatives to provide sessions to their staff members to spread awareness and implement such digital solutions.

Given the rising popularity of digital therapeutics and the emergence of several novel technologies, digital therapeutics companies are integrating advanced techniques to their respective portfolio to ensure higher adoptions. Driven by the growing awareness among patients and active efforts undertaken by the government, as well as industry stakeholders to meet the existing demand, the digital therapeutics market is expected to witness lucrative growth opportunities.

DIGITAL THERAPEUTICS MARKET: KEY INSIGHTS

The report delves into the current state of the digital therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• At present, over 415 digital therapeutics are either commercially available or under development for various target indications; more than 45% of such solutions are offered as standalone software applications.

• Amongst these, 220 digital solutions are focused on women's health; around 30% of such solutions target reproductive health related applications.
• 150+ developers are engaged in the development / evaluation of digital therapeutic solutions, targeting different age groups and a wide range of disease indications.
• In pursuit of gaining a competitive edge, the digital therapeutic solution developers are focused on the integration of advanced features into their respective products and affiliated offerings.
• More than 1.6 million patients have been recruited / enrolled across 500+ clinical trials registered for this novel class of therapies; nearly 40% of such studies are still actively recruiting patients.
• To support the ongoing innovation in this field, several private and public investors have made substantial capital investments, amounting to over USD 8 billion, across ~370 instances.
• Owing to the growing interest and lucrative opportunity associated with this domain, industry stakeholders are actively forging partnerships; ~20% of the deals have been focused on the commercialization of proprietary solutions.
• In order to promote the adoption of their digital health solutions, developers are exploring various marketing strategies that highlight the key features of their products, across a number of platforms.
• Given the rising incidence of chronic clinical conditions and the recent surge in demand for remote and digital health solutions, the market for digital therapeutics is anticipated to grow at a CAGR of ~20%, till 2035.

DIGITAL THERAPEUTICS MARKET: KEY SEGMENTS

Currently, Software Solutions Occupy the Largest Share of the Digital Therapeutics Market

Based on the type of solution, the market is segmented into software solution, gaming solution and combination solution. At present, the software solution segment holds the maximum share of the digital therapeutics market. This trend is unlikely to change in the near future.

Curative Solutions are Likely to Dominate the Digital Therapeutics Market During the Forecast Period

Based on the type of therapy, the market is segmented into curative and preventive solutions. At present, curative solution holds the maximum share within the digital therapeutics market. This trend is likely to remain the same in the forthcoming years.

Medication Replacement Solutions Segment is Likely to Dominate the Digital Therapeutics Market During the Forecast Period

Based on the purpose of solution, the market is segmented into medication replacement solutions and medical augmentation solutions. At present, medication replacement solution holds a larger share of the digital therapeutics market. This trend is likely to remain the same in the coming decade. It is worth highlighting that medical augmentation solution is likely to grow at a relatively higher CAGR.

Currently, B2B Model Occupies the Largest Share of the Digital Therapeutics Market

Based on the business model, the market is segmented into B2B and B2C. It is worth highlighting that majority of the current digital therapeutics market is captured by the B2B model.

Metabolic Disorders Account for the Largest Share of the Digital Therapeutics Market

Based on the target therapeutic area, the market is segmented into cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders respiratory disorders, sleep disorders, substance use disorders and other disorders. While metabolic disorders account for a relatively higher market share, it is worth highlighting that the neurological disorders segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, Latin America, and the Rest of the world. The majority share is expected to be captured by developers based in North America. It is worth highlighting that, over the years, the market in Asia is expected to grow at a higher CAGR.

Example Players in the Digital Therapeutics Market

• Ampersand Health
• Akili Interactives
• Better Therapeutics
• Brain+
• Click Therapeutics
• CogniFit
• GAIA
• Healios
• JOGO Health
• Jolly Good
• KORE Digital Health Therapeutics
• Livongo Health
• Lucid
• MedRhythms
• Pear Therapeutics
• Redicare Control
• Susmed
• The Learning Corp
• Voluntis
• WellDoc

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief of Staffs to CEO and Strategy Lead, Ampersand Health
• Ex-Chief Executive Officer, Canary Health
• Marketing Director, Dnurse Technology
• Chief Strategy Officer, EMBR Labs
• Founder and Chief Executive Officer, Exosystems
• Chief Executive Officer, Floreo
• Chief Commercial Officer, GAIA
• Chairman and Chief Executive Officer, Healios
• Co-Founder and President, Joggo Health
• Chief Executive Officer, metaMe Health
• Chief Executive Officer, SelfBack
• Ex-Chief Executive Officer, Somatix
• Chief Executive Officer, Tilak Healthcare
• Chief Executive Officer, Turnaround Health
• Co-Founder and Chief Executive Officer, Vida Health
• Ex-Communication Manager, Voluntis
• Ex-Vice President Marketing, Ex-Senior Manager Consumer Marketing, and Ex-Marketing and Public Relations, Wellthy Therapeutics
• Founder and Chief Executive Officer, Undisclosed

DIGITAL THERAPEUTICS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the digital therapeutics market, focusing on key market segments, including [A] type of solution, [B] type of therapy, [C] purpose of solution, [D] type of business model, [E] target therapeutic area and [F] key geographical regions.
• Market Landscape: A comprehensive evaluation of digital therapeutics solutions, considering various parameters, such as [A] status of development, [B] type of solution, [C] type of therapy, [D] purpose of solution, [E] target indication(s), [F] therapeutic area and [G] target population. Additionally, it includes information related to digital therapeutics solution developers, highlighting their [H] year of establishment, [I] company size, [J] type of business model and [K] location of their headquarters.
• Product Competitiveness Analysis: A comprehensive competitive analysis of digital therapeutics solutions, examining factors, such as [A] product portfolio (based on the number of digital therapeutic solutions being developed for that therapeutic area) and [B] key product specific parameters (such as status of development, type of solution, type of therapy, prescription requirement and purpose of solution).
• Company Profiles: In-depth profiles of key industry players that are either offering or engaged in the development of digital therapeutics solutions, focusing on [A] company overviews, [B] product portfolio, [C] recent developments and [D] an informed future outlook.
• Clinical Trials Analysis: Examination of completed, ongoing, and planned clinical studies of various digital therapeutics, based on parameters like [A] trial registration year, [B] trial phase, [C] number of patients enrolled, [D] study design, [E] trial recruitment status and trial focus, [F] type of organization, [G] regional distribution of trials and [H] an insightful clinical end-points analysis (for top ten recent initiated trials for popular therapeutic areas).
• Funding and Investment Analysis: A detailed evaluation of the investments made in the digital therapeutics' market, encompassing grants, debt financing, seed funding, venture series, initial public offering, secondary offerings, private placements and other equity.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2016, covering marketing and distribution agreements, mergers / acquisitions, pilot product offerings, product / technology integration agreements, product / technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, product development agreements, research and development agreements, and commercialization agreements.
• Go-To-Market Strategy: A detailed analysis of various business models and go-to-market strategies adopted by firms engaged in developing digital therapeutics solutions, highlighting details on various channels adopted by the stakeholders in order to raise awareness and offer access to their proprietary products.
• Bowman's Clock Pricing Strategy: A Bowman's clock pricing strategy framework evaluates the competitive position of various companies within this sector by examining their product prices and features. Additionally, it introduces an equation designed to estimate the potential price of digital therapeutics based on their attributes.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1 Chapter Overview
• 3.2. Digitization in the Healthcare Sector
• 3.3. Next-Generation Healthcare Solutions
• 3.4. Key Concepts Associated with Digital Health Solutions
  • 3.4.1. Cognitive Behavioral Therapy (CBT)
  • 3.4.2. Internet of Things (IoT)
  • 3.4.3. Big Data
  • 3.4.4. Artificial Intelligence (AI)
  • 3.4.5. Gamification
• 3.5. Overview of Digital Therapeutics
  • 3.5.1. Key Strategic Initiatives
    • 3.5.1.1. Digital Therapeutics Alliance (DTA)
    • 3.5.1.2. Personal Connected Health (PCH) Alliance
    • 3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
    • 3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
    • 3.5.1.5. National Health Service (NHS) Guidelines
    • 3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
  • 3.5.2. Typical Development and Commercialization Path for Digital Therapeutics
    • 3.5.2.1. Discovery and Preclinical Phase
    • 3.5.2.2. Clinical Trials and Validation
    • 3.5.2.3. Negotiation Involving Insurance Providers / Payers
    • 3.5.2.4. Distribution and Marketing
• 3.6 Concluding Remarks

4. CURRENT MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. Digital Therapeutics: Overall Market Landscape
  • 4.2.1. Analysis by Status of Development
  • 4.2.2. Analysis by Type of Solution
  • 4.2.3. Analysis by Type of Therapy
  • 4.2.4. Analysis by Purpose of Solution
  • 4.2.5. Analysis by Target Indication
  • 4.2.6. Analysis by Therapeutic Area
  • 4.2.7. Analysis by Target Population
• 4.3. Digital Therapeutics: Additional Information
  • 4.3.1. Analysis by Requirement of Prescription
  • 4.3.2. Analysis by Duration of Course
  • 4.3.3. Analysis by Cost of Solution
• 4.4. Digital Therapeutics: List of Developers
  • 4.4.1. Analysis by Year of Establishment
  • 4.4.2. Analysis by Company Size
  • 4.4.3. Analysis by Type of Business Model
  • 4.4.4 Analysis by Location of Headquarters
• 4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
• 4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
• 4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
• 4.8. Analysis of Regional Activity (World Map Representation)

5. PRODUCT COMPETITIVENESS ANALYSIS

• 5.1. Chapter Overview
• 5.2. Assumptions / Key Parameter
• 5.3. Methodology
• 5.4. Key Therapeutic Areas
  • 5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders
  • 5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
  • 5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders
  • 5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders
  • 5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders
  • 5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. Akili Interactive
  • 6.2.1 Company Overview
  • 6.2.2. Product Portfolio
  • 6.2.3. Recent Developments and Future Outlook
• 6.3. Big Health
  • 6.3.1. Company Overview
  • 6.3.2. Product Portfolio
  • 6.3.3. Recent Developments and Future Outlook
• 6.4. dreem
  • 6.4.1. Company Overview
  • 6.4.2. Product Portfolio
  • 6.4.3. Recent Developments and Future Outlook
• 6.5 Kaia Health
  • 6.5.1. Company Overview
  • 6.5.2. Product Portfolio
  • 6.5.3. Recent Developments and Future Outlook
• 6.6. MindMaze
  • 6.6.1. Company Overview
  • 6.6.2. Product Portfolio
  • 6.6.3. Recent Developments and Future Outlook
• 6.7. Omada Health
  • 6.7.1. Company Overview
  • 6.7.2. Product Portfolio
  • 6.7.3. Recent Developments and Future Outlook
• 6.8. Pear Therapeutics
  • 6.8.1. Company Overview
  • 6.8.2. Product Portfolio
  • 6.8.3 Recent Developments and Future Outlook
• 6.9. Vida Health
  • 6.9.1. Company Overview
  • 6.9.2. Product Portfolio
  • 6.9.3. Recent Developments and Future Outlook
• 6.10. Voluntis
  • 6.10.1. Company Overview
  • 6.10.2. Product Portfolio
  • 6.10.3. Recent Developments and Future Outlook
• 6.11. WellDoc
  • 6.11.1. Company Overview
  • 6.11.2. Product Portfolio
  • 6.11.3. Recent Developments and Future Outlook
• 6.12. Wellthy Therapeutics
  • 6.12.1. Company Overview
  • 6.12.2. Product Portfolio
  • 6.12.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

• 7.1. Chapter Overview
• 7.2. Scope and Methodology
• 7.3. Digital Therapeutics: Clinical Trial Analysis
  • 7.3.1. Analysis by Trial Registration Year
  • 7.3.2. Analysis by Trial Status
  • 7.3.3. Analysis by Trial Registration Year and Trial Status
  • 7.3.4. Analysis by Trial Phase
  • 7.3.5. Analysis by Type of Study
  • 7.3.6. Analysis by Study Design
  • 7.3.7. Analysis by Study Age
  • 7.3.8. Analysis by Gender of Patients
  • 7.3.9. Analysis of Patients Enrolled by Trial Registration Year
  • 7.3.10. Analysis by Type of Sponsor
  • 7.3.11. Analysis by Focus Area
  • 7.3.12. Analysis by Geography
  • 7.3.13. Analysis by Trial Registration Year, Recruitment Status and Geography
  • 7.3.14. Analysis of Patients Enrolled by Geography
• 7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS

• 8.1. Chapter Overview
• 8.2. Type of Funding Models
• 8.3. Digital therapeutics: List of Funding and Investments
  • 8.3.1 Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
  • 8.3.2. Analysis of Funding Instances by Year
  • 8.3.3. Analysis of Amount Invested by Year
  • 8.3.4. Analysis by Type of Funding
  • 8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
  • 8.3.6. Analysis by Therapeutic Area
  • 8.3.7. Analysis by Geography
  • 8.3.8. Most Active Players: Analysis by Number of Instances
  • 8.3.9. Most Active Players: Analysis by Amount Raised
  • 8.3.10. Most Active Investors: Analysis by Number of Instances
• 8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. Digital Therapeutics: List of Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
    • 9.3.2.1. Analysis by Year of Partnership and Type of Partnership
    • 9.3.2.2. Analysis by Type of Partnership and Company Size
  • 9.3.3. Analysis by Type of Partner
    • 9.3.3.1. Analysis by Year of Partnership and Type of Partner
    • 9.3.3.2. Analysis by Type of Partnership and Type of Partner
    • 9.3.3.3 Analysis by Type of Partner and Company Size
  • 9.3.4. Analysis by Type of Therapy
    • 9.3.4.1. Analysis by Type of Partnership and Type of Therapy
    • 9.3.4.2. Analysis by Type of Partner and Type of Therapy
  • 9.3.5. Analysis by Therapeutic Area
    • 9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
    • 9.3.5.2 Analysis by Type of Partner and Therapeutic Area
  • 9.3.6. Most Active Players: Analysis by Number of Partnerships
  • 9.3.7. Analysis by Geography
  • 9.3.8. Intercontinental and Intracontinental Agreements

10. GO-TO-MARKET STRATEGY

• 10.1. Chapter Overview
• 10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
  • 10.2.1. Participation in Global Events
  • 10.2.2. Marketing on Social Media Platforms
  • 10.2.3. Marketing on Online / Print Media Platforms
  • 10.2.4. Undertaking Various Promotional Activities through Official Websites
  • 10.2.5. Adoption of Different Business Models
    • 10.2.5.1. B2C Business Model
    • 10.2.5.2. B2B Business Model
    • 10.2.5.2. B2B2C Business Model
  • 10.2.6. Undertaking Various Promotional Activities through Product Add-ons
• 10.3. Concluding Remarks

11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS

• 11.1. Chapter Overview
• 11.2. Bowman Strategy Clock
  • 11.2.1. Two Dimensions of Bowman Strategy Clock
  • 11.2.2. Eight Positions on Bowman Strategic Clock
• 11.3 Roots Analysis Framework
  • 11.3.1. Methodology
  • 11.3.2. Theoretical Framework and Price Evaluation Hypothesis
  • 11.3.3. Results and Interpretation
    • 11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
    • 11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
    • 11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
    • 11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
    • 11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
    • 11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
    • 11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
    • 11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
• 11.4. Concluding Remarks

12. MARKET FORECAST

• 12.1. Chapter Overview
• 12.2. Forecast Methodology and Key Assumptions
• 12.3. Global Digital Therapeutics Market, till 2035
• 12.4. Digital Therapeutics Market: Analysis by Type of Solution, till 2035
  • 12.4.1. Digital Therapeutics Market for Standalone Software Applications, till 2035
  • 12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, till 2035
  • 12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, till 2035
  • 12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, till 2035
  • 12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), till 2035
  • 12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), till 2035
  • 12.4.7. Digital Therapeutics Market for Other Types of Solutions, till 2035
• 12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, till 2035
  • 12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, till 2035
  • 12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, till 2035
• 12.6. Digital Therapeutics Market: Analysis by Type of Therapy, till 2035
  • 12.6.1 Digital Therapeutics Market for Curative Therapy, till 2035
  • 12.6.2. Digital Therapeutics Market for Preventive Therapy, till 2035
• 12.7. Digital Therapeutics Market: Analysis by Business Model, till 2035
  • 12.7.1. Digital Therapeutics Market for B2C Model, till 2035
  • 12.7.2. Digital Therapeutics Market for B2B Model, till 2035
• 12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, till 2035
  • 12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, till 2035
  • 12.8.2. Digital Therapeutics Market for Chronic Pain, till 2035
  • 12.8.3. Digital Therapeutics Market for Mental Health Problems, till 2035
  • 12.8.4. Digital Therapeutics Market for Metabolic Disorders, till 2035
  • 12.8.5. Digital Therapeutics Market for Neurological Disorders, till 2035
  • 12.8.6. Digital Therapeutics Market for Respiratory Disorders, till 2035
  • 12.8.7. Digital Therapeutics Market for Sleep Disorders, till 2035
  • 12.8.8. Digital Therapeutics Market for Substance Use Disorders, till 2035
  • 12.8.9. Digital Therapeutics Market for Other Disorders, till 2035
• 12.9. Digital Therapeutics Market: Analysis by Geography, till 2035
  • 12.9.1. Digital Therapeutics Market in North America, till 2035
  • 12.9.2. Digital Therapeutics Market in Europe, till 2035
  • 12.9.3. Digital Therapeutics Market in Asia, till 2035
  • 12.9.4. Digital Therapeutics Market in MENA, till 2035
  • 12.9.5. Digital Therapeutics Market in Latin America, till 2035
  • 12.9.6. Digital Therapeutics Market in Rest of the World, till 2035
• 12.10. Concluding Remarks

13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT

• 13.1. Introduction: Women Digital Health
• 13.2. Chapter Overview
• 13.3. Women's Digital Health: Product Pipeline
  • 13.3.1. Analysis by Type of Solution
  • 13.3.2. Analysis by Status of Development
  • 13.3.3. Analysis by Product Ratings
  • 13.3.4. Analysis by Application Area
  • 13.3.5. Analysis of Products by Different Stages of Pregnancy
  • 13.3.6. Analysis by Purpose of Solution
  • 13.3.7. Analysis by Type of End-Users
  • 13.3.8. Analysis by Type of Solution and Application Area
• 13.4. Women's Digital Health: Developer's Landscape
  • 13.4.1. Analysis by Year of Establishment
  • 13.4.2. Analysis by Company Size
  • 13.4.3. Analysis by Location of Headquarters (Region-wise)
  • 13.4.4. Analysis by Company Size and Region
  • 13.4.5. Analysis by Location of Headquarters (Country-Wise)
  • 13.4.6. Leading Players: Analysis by Number of Solutions
  • 13.4.7. Regional Landscape: Analysis by Type of Solution

14. SWOT ANALYSIS

• 14.1. Chapter Overview
• 14.2. Comparison of SWOT Factors
  • 14.2.1. Strengths
  • 14.2.2. Weaknesses
  • 14.2.3. Opportunities
  • 14.2.4. Threats
  • 14.2.5. Conclusion

15. EXECUTIVE INSIGHTS

• 15.1. Chapter Overview
• 15.2. Ampersand Health
  • 15.2.1. Company Snapshot
  • 15.2.2. Interview Transcript: Chief of Staffs to CEO and Strategy Lead
• 15.3. Canary Health
  • 15.3.1. Company Snapshot
  • 15.3.2. Interview Transcript: Ex-Chief Executive Officer
• 15.4. Dnurse Technology
  • 15.4.1. Company Snapshot
  • 15.4.2. Interview Transcript: Marketing Director
• 15.5. Embr Labs
  • 15.5.1. Company Snapshot
  • 15.5.2. Interview Transcript: Chief Strategy Officer
• 15.6. Exosystems
  • 15.6.1. Company Snapshot
  • 15.6.2. Interview Transcript: Founder and Chief Executive Officer
• 15.7. Floreo
  • 15.7.1. Company Snapshot
  • 15.7.2. Interview Transcript: Chief Executive Officer
• 15.8. GAIA
  • 15.8.1. Company Snapshot
  • 15.8.2. Interview Transcript: Chief Commercial Officer
• 15.9. Healios
  • 15.9.1. Company Snapshot
  • 15.9.2. Interview Transcript: Founder and Chief Executive Officer
• 15.10 JOGGO Health
  • 15.10.1. Company Snapshot
  • 15.10.2. Interview Transcript: Co-Founder and President
• 15.11. metaMe Health
  • 15.11.1. Company Snapshot
  • 15.11.2 Interview Transcript: Chief Executive Officer
• 15.12. SelfBack
  • 15.12.1. Company Snapshot
  • 15.12.2. Interview Transcript: Chief Executive Officer
• 15.13. Somatix
  • 15.13.1. Company Snapshot
  • 15.13.2. Interview Transcript: Ex-Chief Executive Officer
• 15.14. Tilak Healthcare
  • 15.14.1. Company Snapshot
  • 15.14.2. Interview Transcript: Chief Executive Officer
• 15.15. Turnaround Health
  • 15.15.1. Company Snapshot
  • 15.15.2. Interview Transcript: Chief Executive Officer
• 15.16. Vida Health
  • 15.16.1. Company Snapshot
  • 15.16.2. Interview Transcript: Co-Founder and Chief Executive Officer
• 15.17. Voluntis
  • 15.17.1. Company Snapshot
  • 15.17.2. Interview Transcript: Ex-Communication Manager
• 15.18. Wellthy Therapeutics
  • 15.18.1. Company Snapshot
  • 15.18.2. Interview Transcript: Ex-Vice President Marketing, Ex-Senior Manager Consumer Marketing, and Ex-Marketing and Public Relations
• 15.19. Undisclosed
  • 15.19.1. Interview Transcript: Founder and Chief Executive Officer

16. CONCLUDING REMARKS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료